Tacrolimus 13CD2
| Product Name | Tacrolimus 13CD2 |
|---|---|
| Alternate Names | Tacrolimus Stable Isotopes, Stable Isotopes of Tacrolimus |
| CAT No. | CS-O-03122 |
| CAS No. | 1356841-89-8 |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 807.02 g/mol |
| Mol. For. | C₄₃¹³CH₆₇D₂NO₁₂ |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Tacrolimus |
| Purity | >98% |
| Therapeutic | Immunosuppressants |
| Smileys | CC1CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC(=O)C(C=C(C1)C)CC=C)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC |
| Canonical Smiles | CC1CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC(=O)C(C=C(C1)C)CC=C)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC |
| InchIKey | QJJXYPPXXYFBGM-OTZVSDQDSA-N |
| Inchl | InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19-,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1/i1+1D2 |
| IUPAC | (1R,9S,12S,13R,14S,17R,18Z,21S,23S,24R,25S,27R)-17-(3,3-dideuterio(313C)prop-2-enyl)-1,14-dihydroxy-12-[(E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Tacrolimus 13CD2, also known as Tacrolimus-D2, is an isotopically labeled version of the immunosuppressive drug Tacrolimus. This medication is primarily used in organ transplant patients to prevent rejection of the transplanted organ by suppressing the immune system. Tacrolimus 13CD2 works by inhibiting the activity of T lymphocytes, which are responsible for the rejection of transplanted organs. Due to its potent immunosuppressive properties, Tacrolimus 13CD2 is also used in the treatment of other autoimmune diseases such as psoriasis, atopic dermatitis, and uveitis.
The chemical formula of Tacrolimus 13CD2 is C44H69D2NO12, and it has a molecular weight of 822.09 g/mol. It is a macrolide lactone compound and belongs to the family of calcineurin inhibitors. Tacrolimus 13CD2 is available in the form of capsules, ointment, or injection.
Tacrolimus 13CD2 is metabolized in the liver and excreted in urine and feces. The drug has a half-life of approximately 12 hours and reaches its maximum concentration in the blood within 1-3 hours of administration. Tacrolimus 13CD2 should be used with caution in patients with liver or kidney disease, and its dosage should be adjusted accordingly.
In conclusion, Tacrolimus 13CD2 is a potent immunosuppressive drug used in the prevention of organ rejection in transplant patients and treatment of autoimmune diseases. Its isotopically labeled version, Tacrolimus-D2, is used in pharmacokinetic and pharmacodynamic studies to determine the drug's metabolism and mechanism of action.
Get an Instant Quote
Related Compounds
Tacrolimus D3 | Tacrolimus D5 | Tacrolimus-13CD4 | Tacrolimus 13C D5 |